Lenalidomide‐Dexamethasone as an Effective and Well‐Tolerated Treatment Option for Refractory Rosai‐Dorfman‐Destombes Disease: A Clinical and Pharmacophenomic Study
Key Points
Assess the efficacy and tolerability of lenalidomide-dexamethasone in treating refractory Rosai-Dorfman-Destombes disease.
Conducted a clinical evaluation of treatment outcomes.
Utilized pharmacophenomic analysis to assess drug response.
Collaborated with the Coastal Rare Inflammatory Diseases Program and Every Cure.
Showed significant improvement in disease symptoms after treatment.
Demonstrated high tolerability with minimal side effects.
Abstract
A combined clinical and computational pharmacophenomic study from the Coastal Rare Inflammatory Diseases Program and Every Cure.
Lenalidomide‐Dexamethasone as an Effective and Well‐Tolerated Treatment Option for Refractory Rosai‐Dorfman‐Destombes Disease: A Clinical and Pharmacophenomic Study | Synapse